Can a Two-Drug combo beat back Tough-to-Treat hairy cell leukemia?
NCT ID NCT01059786
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the antibody rituximab to either pentostatin or bendamustine can improve outcomes for people with hairy cell leukemia that has relapsed or not responded to standard treatments. Participants are randomly assigned to one of the two drug combinations and receive four 28-day cycles of treatment. The study aims to see which combination leads to a better response, including complete or partial remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rituximab combined with either pentostatin or bendamustine
- What this could lead to
- If successful, this could point toward a more effective treatment option for people with hairy cell leukemia that has stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not apply to everyone. Both drug combinations can cause side effects, and it is not yet known which, if either, is superior.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug duo aims to tackle rare leukemia
- New registry aims to unlock secrets of rare leukemia
- Engineered immune cells take aim at stubborn blood cancers
- New combo therapy targets rare blood cancer in early trial
- New combo aims to tame hairy cell leukemia with fewer side effects
- Engineered t cells take on tough leukemia and lymphoma